Preliminary experience with intravenous GADOXETATE DISODIUM (cas 135326-22-6) as a craniospinal MR contrast agent
-
Add time:08/10/2019 Source:sciencedirect.com
IntroductionGADOXETATE DISODIUM (cas 135326-22-6) is a gadolinium-based contrast agent (GBCA) typically used for body imaging, as about 50% of its excretion is via the liver. Its use for craniospinal MRI has not been reported.
We also recommend Trading Suppliers and Manufacturers of GADOXETATE DISODIUM (cas 135326-22-6). Pls Click Website Link as below: cas 135326-22-6 suppliers
Prev:Liver enhancement in healthy dogs after Gadoxetic acid (cas 135326-11-3) administration during dynamic contrast-enhanced magnetic resonance imaging
Next:Reducing artifacts of GADOXETATE DISODIUM (cas 135326-22-6)-enhanced MRI with oxygen inhalation in patients with prior episode of arterial phase motion: intra-individual comparison) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI08/19/2019
- Feasibility of GADOXETATE DISODIUM (cas 135326-22-6)-enhanced MR cholangiography in chronic cholestatic biliary disease08/18/2019
- Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma08/17/2019
- Evaluation of cystic duct patency: comparison of functional MR cholangiography with GADOXETATE DISODIUM (cas 135326-22-6) and hepatobiliary scintigraphy in suspected acute cholecystitis08/16/2019
- Abdominal vasculature in dynamic contrast-enhanced liver MRI at 3.0 T: an intraindividual comparative study using GADOXETATE DISODIUM (cas 135326-22-6) and gadofosveset trisodium08/15/2019
- Distinguishing hemangiomas from metastases on liver MRI performed with GADOXETATE DISODIUM (cas 135326-22-6): Value of the extended washout sign08/14/2019
- Imaging findings of primary hepatic angiosarcoma on GADOXETATE DISODIUM (cas 135326-22-6)-enhanced liver MRI: comparison with hepatic haemangiomas of similar size08/13/2019
- GADOXETATE DISODIUM (cas 135326-22-6) enhanced spectral dual-energy CT for evaluation of cholangiocarcinoma: Preliminary data08/12/2019
- Reducing artifacts of GADOXETATE DISODIUM (cas 135326-22-6)-enhanced MRI with oxygen inhalation in patients with prior episode of arterial phase motion: intra-individual comparison08/11/2019
-
Health and Chemical more >
-
Related Products
- Disodium (1-methyl-4-oxoimidazolidin-2-ylidene)phosphoramidate
- Disodium 1,3,4-thiadiazole-2,5-dithiolate
- Disodium 1,5-naphthalenedisulfonate
- Disodium 2-(4-styryl-3-sulfophenyl)-7-sulfo-2H-naphtho(1,2-d)triazole
- Disodium 2,2'-dihydroxy-4,4'-dimethoxy-5,5'-disulfobenzophenone
- Disodium 2,5-dihydro-5-thiooxo-1H-tetrazol-1-ylmethanesulfonate
- Disodium 2-naphthol-3,6-disulfonate
- Disodium 2-naphthol-3,7-disulfonate
- Disodium 2-oxoglutarate dihydrate
- Disodium 3-(2-hydroxyphenyl)-8-sulphonatobenzo(f)quinoline-1-carboxylate